MediciNova Receives Buy Rating with $9.00 Price Target from D. Boral Capital Analyst Jason Kolbert.

MediciNova (MNOV) receives a "Buy" rating and a $9.00 price target from analyst Jason Kolbert at D. Boral Capital. The rating and target are unchanged, indicating confidence in the company's current trajectory. Two analysts have a one-year price target average of $7.00, with an upside of 455.78% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

MediciNova Inc. (MNOV), a biopharmaceutical company focused on developing therapeutics for serious diseases, has received a positive outlook from analyst Jason Kolbert at D. Boral Capital. Kolbert maintains a "Buy" rating on the stock with a price target of $9.00, indicating confidence in the company's current trajectory and future prospects [2].

The unchanged price target and rating suggest that Kolbert remains bullish on MediciNova's (MNOV) potential. The company's pipeline includes MN-166 (ibudilast) for neurological and other disorders, MN-001 (tipelukast) for fibrotic and other diseases, and MN-221 (bedoradrine) for acute exacerbation of asthma, among others [1].

Analysts' consensus indicates a one-year price target average of $7.00, with a high estimate of $9.00 and a low estimate of $5.00. This average target implies an upside of 455.78% from the current price of $1.26. Additionally, the average brokerage recommendation is 2.0, indicating an "Outperform" status [2].

MediciNova's recent earnings reports have shown promising results, with the company reporting earnings for the first quarter ended March 31, 2025. The company has also made significant strides in clinical trials and received patent approvals, further bolstering its market position [1].

Investors should closely monitor MediciNova's (MNOV) progress as the company continues to develop and commercialize its pipeline of innovative therapeutics. The positive analyst outlook and consistent performance indicators suggest that MediciNova remains a strong contender in the biotech sector.

References:
[1] https://www.marketscreener.com/quote/stock/MEDICINOVA-INC-38688/
[2] https://www.gurufocus.com/news/3001707/medicinova-mnov-receives-buy-rating-with-900-price-target-mnov-stock-news